The referenced media source is missing and needs to be re-embedded.
Paul Baas, MD – IASLC Virtual Presidential Symposium Presentation
About the authors
Related Articles
-
Tarlatamab Emerges as New Standard of Care in Second-Line SCLC, with Significant Gains in OS, PFS
-
A Paradigm Shift: Final 5-Year Overall Survival Results from CheckMate 816 in Resectable NSCLC
-
Lurbinectedin and Atezolizumab Combo Demonstrates Survival Benefit in ES-SCLC
-
Early Data Suggest that a 14-Gene Molecular Assay May Help Predict Recurrence Risk in Patients with Early-Stage Non-Squamous NSCLC